Autolysosomal activation combined with lysosomal destabilization efficiently targets myeloid leukemia cells for cell death.

In conclusion, mefloquine treatment combined with mTOR inhibition synergistically induced targeted ML cell death without additional toxicity. Taken together, these data provide a molecular mechanism and thus a rationale for a therapeutic approach for specific targeting of ML lysosomes.